Biohaven Ltd.

The current price of BHVN is $15.24 — it has decreased by 2.37% since the previous close. Data as of Nov 4, 2026.

BHVN is down 1.42% over the past week, up 18.41% over the past month and up 9.25% over the past year. The price is above its 200-day moving average of $12.25.

Analysts' average 12-month price target for BHVN is $24.67, which implies 61.88% upside from the current price. Individual estimates range from $11.00 to $48.00.

Of the 17 analysts covering Biohaven Ltd., 3 rate it a strong buy, 9 rate it a buy, 4 rate it a hold and 1 rates it a strong sell. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Biohaven Ltd. has a market capitalization of $2.3B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Biohaven Ltd. posted a loss of $0.86 per share against an estimate of -$0.7833, missing expectations by 9.79%. Upcoming reports are listed in the earnings calendar.

Biohaven Ltd. has not paid any dividends over the past year.

Companies most comparable to Biohaven Ltd. include AbCellera Biologics Inc., Pharvaris N.V., Celldex Therapeutics, Inc., Immunome, Inc. and Vera Therapeutics, Inc.

In the latest trading session BHVN moved between $15.13 and $16.13, a range of 6.56% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Biohaven Ltd. shows a buy rating today and a buy rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Biohaven Ltd. is sell. Technical ratings are indicators, not investment advice.

Over the past 52 weeks BHVN has traded between $7.48 and $18.24. The current price is 16.45% below its 52-week high.